Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

“…Cabazitaxel was also associated with an increased rate of pain response and delayed time to pain progression and skeletal-related events. 22 Panel consensus was that results of CARD provide level 1 evidence supporting cabazitaxel over abiraterone or enzalutamide in patients who have already received docetaxel and either abiraterone or enzalutamide. Therefore, the panel included cabazitaxel as a category 1, preferred option for patients with prior docetaxel and prior novel hormone therapy in the metastatic CRPC setting (see PROS-16, page 136).…”

Upregulation of ATP Binding Cassette Subfamily C Member 5 facilitates Prostate Cancer progression and Enzalutamide resistance via the CDK1-mediated AR Ser81 Phosphorylation Pathway

“…As a type of advanced prostate cancer with a poor prognosis, metastatic castration-resistant prostate cancer (mCRPC) has attracted increasing attention from scholars and physicians [7,8]. Particularly for patients with metastatic and castration-resistant prostate cancer, combination regimens including androgen deprivation therapy and radiotherapy and chemotherapy are not sufficiently effective [9][10][11][12][13][14][15]. The search for new and effective drug targets is important for improving the efficacy of prostate cancer treatment.…”

An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer

“…In the CARD study, which compared cabazitaxel with abiraterone or enzalutamide in patients with mCRPC who had received prior docetaxel and had previously progressed within 12 months while receiving the alternative androgensignaling-targeted inhibitor (abiraterone or enzalutamide), the median time to FACT-P TS deterioration was 14.8 months [95% confidence interval (CI) 6.3 to not estimable (NE)] with cabazitaxel versus 8.9 months (95% CI 6.3 to NE) with abiraterone or enzalutamide (hazard ratio 0.72, 95% CI 0.44-1.20; log-rank P ¼ 0.21). 33 The median radiographic progression-free survival was significantly longer (8.0 months versus 3.7 months) among patients who received cabazitaxel compared with abiraterone or enzalutamide, which may explain why the time to FACT-P TS deterioration was shorter among patients who received abiraterone or enzalutamide. 34 In the phase III COU-AA-302 and PREVAIL trials in chemotherapy-naive mCRPC, HRQL data have been reported.…”